Compare Edwards Lifesciences Corporation Common Stock (EW) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs VanEck Australian Floating Rate ETF — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while VanEck Australian Floating Rate ETF trades at $50.96 (market cap $11.24B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 4.4× VanEck Australian Floating Rate ETF's market cap, and VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Edwards Lifesciences Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| EW | FLOT | |
|---|---|---|
Market Cap | $49.44B | $11.24B |
Volume | 3,508,027 | 2,285,826 |
Sector | Health | Fixed Income |
52-Week High | $95.18 | $51.07 |
52-Week Low | $72.65 | $50.72 |
Enterprise Value | $45.90B | — |
Typical Hold Time | — | 21 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLOT trades at $50.91 with minimal daily movement (-0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent dividend distributions of $0.17-$0.18 highlight income generation. The ETF benefits from floating rate exposure amid Fed tightening cycles, though concentration risk in bank holdings (47% exposure) warrants attention.
Outlook remains tied to interest rate trajectory, with FLOT positioned to benefit from higher rates. Key risks include bank sector concentration and Fed policy shifts. The current technical weakness suggests cautious near-term momentum despite the floating rate advantage in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
